At the proteomic level, differences in the expression of estrogen and progesterone receptors (ER and PgR, respectively), human epidermal growth factor receptor 2 (HER2) and the nuclear protein Ki-67 play an important role in current breast cancer clinical decision-making in terms of prognosis and optimal treatment plan. This evidence concerns the gene PGR and breast carcinoma.